BioStem Technologies Earnings Call Transcripts

Fiscal Year 2026

Micro-Cap Virtual Conference

A strategic shift to a surgical-centric model, expanded board, and Nasdaq uplisting have positioned the company to target a $26 billion market with a diversified, clinically proven product portfolio. Sequential revenue growth, margin recovery plans, and strong clinical evidence support a positive outlook.

Read full transcript →
Earnings Call: Q2 2026
Revenue grew to $7.9M in Q2 2026, driven by hospital segment expansion and commercial investments. Gross margin held at 61%, with guidance raised to $26–$29M for the year. Uplisting to Nasdaq and new patents support growth, while a $10M milestone payment is pending.

Read full transcript →

Quarterly report
Earnings release